A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer

Robert Svatek, Jay B. Shah, Jinliang Xing, David Chang, Jie Lin, David J. McConkey, Xifeng Wu, Colin P. Dinney

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND: The current study was conducted to demonstrate the utility of a multiplexed, particle-based flow cytometric assay for the simultaneous analysis of a panel of matrix metalloproteinases (MMPs) using small volumes of plasma samples from patients with bladder cancer. In addition, the authors attempted to test the hypothesis that plasma levels of MMPs are associated with time to cancer-related death. METHODS: Plasma MMP concentrations (MMP-1, -2, -3, -7, -8, -9, and -12) in 135 patients presenting with high-grade ≥T1 bladder cancer were measured. Data regarding clinical and pathologic features was ascertained in a retrospective fashion. RESULTS: The median duration of follow-up was 30.4 months. At the time of analysis, 61 patients had died, including 45 (33.3%) who died of bladder cancer. Plasma MMP-12 was not measurable. For all other MMPs, the intra-assay coefficient of variation varied from 6.12% to 9.82%. MMP-1, -2, -3, -8, and -9 were not found to be significantly associated with time to cancer-related death. Plasma MMP-7 levels were significantly associated with time to cancer-related death after adjustment for competing clinical and pathologic features (hazard ratio [HR], 2.2; 95% confidence interval [95% CI], 1.1-4.5 [P = .022]). The 5-year median cancer-specific survival rates for those patients with MMP-7 levels above and below the median value (300 pg/mL) were 73.6% (95% CI, 60.0-83.2%) and 48.0% (95% CI, 32.5-61.9%), respectively (P = .01). CONCLUSIONS: Multiplexed, particle-based flow cytometric assay allows for the high-throughput measurement of multiple plasma or serum proteins simultaneously. By using this new technology in a cohort of patients with bladder cancer, plasma levels of MMP-7 were identified as being significantly associated with time to cancer-related death.

Original languageEnglish (US)
Pages (from-to)4513-4519
Number of pages7
JournalCancer
Volume116
Issue number19
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 7
Urinary Bladder Neoplasms
Matrix Metalloproteinases
Matrix Metalloproteinase 1
Matrix Metalloproteinase 2
Confidence Intervals
Neoplasms
Blood Proteins
Matrix Metalloproteinase 12
Plasma Volume
Survival Rate
Technology

Keywords

  • Bladder cancer
  • Matrix metalloproteinases
  • MMP-7
  • Plasma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. / Svatek, Robert; Shah, Jay B.; Xing, Jinliang; Chang, David; Lin, Jie; McConkey, David J.; Wu, Xifeng; Dinney, Colin P.

In: Cancer, Vol. 116, No. 19, 01.10.2010, p. 4513-4519.

Research output: Contribution to journalArticle

Svatek, Robert ; Shah, Jay B. ; Xing, Jinliang ; Chang, David ; Lin, Jie ; McConkey, David J. ; Wu, Xifeng ; Dinney, Colin P. / A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. In: Cancer. 2010 ; Vol. 116, No. 19. pp. 4513-4519.
@article{68d3aca0ce194542be9dad55f4dc5a8c,
title = "A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer",
abstract = "BACKGROUND: The current study was conducted to demonstrate the utility of a multiplexed, particle-based flow cytometric assay for the simultaneous analysis of a panel of matrix metalloproteinases (MMPs) using small volumes of plasma samples from patients with bladder cancer. In addition, the authors attempted to test the hypothesis that plasma levels of MMPs are associated with time to cancer-related death. METHODS: Plasma MMP concentrations (MMP-1, -2, -3, -7, -8, -9, and -12) in 135 patients presenting with high-grade ≥T1 bladder cancer were measured. Data regarding clinical and pathologic features was ascertained in a retrospective fashion. RESULTS: The median duration of follow-up was 30.4 months. At the time of analysis, 61 patients had died, including 45 (33.3{\%}) who died of bladder cancer. Plasma MMP-12 was not measurable. For all other MMPs, the intra-assay coefficient of variation varied from 6.12{\%} to 9.82{\%}. MMP-1, -2, -3, -8, and -9 were not found to be significantly associated with time to cancer-related death. Plasma MMP-7 levels were significantly associated with time to cancer-related death after adjustment for competing clinical and pathologic features (hazard ratio [HR], 2.2; 95{\%} confidence interval [95{\%} CI], 1.1-4.5 [P = .022]). The 5-year median cancer-specific survival rates for those patients with MMP-7 levels above and below the median value (300 pg/mL) were 73.6{\%} (95{\%} CI, 60.0-83.2{\%}) and 48.0{\%} (95{\%} CI, 32.5-61.9{\%}), respectively (P = .01). CONCLUSIONS: Multiplexed, particle-based flow cytometric assay allows for the high-throughput measurement of multiple plasma or serum proteins simultaneously. By using this new technology in a cohort of patients with bladder cancer, plasma levels of MMP-7 were identified as being significantly associated with time to cancer-related death.",
keywords = "Bladder cancer, Matrix metalloproteinases, MMP-7, Plasma",
author = "Robert Svatek and Shah, {Jay B.} and Jinliang Xing and David Chang and Jie Lin and McConkey, {David J.} and Xifeng Wu and Dinney, {Colin P.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1002/cncr.25401",
language = "English (US)",
volume = "116",
pages = "4513--4519",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer

AU - Svatek, Robert

AU - Shah, Jay B.

AU - Xing, Jinliang

AU - Chang, David

AU - Lin, Jie

AU - McConkey, David J.

AU - Wu, Xifeng

AU - Dinney, Colin P.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - BACKGROUND: The current study was conducted to demonstrate the utility of a multiplexed, particle-based flow cytometric assay for the simultaneous analysis of a panel of matrix metalloproteinases (MMPs) using small volumes of plasma samples from patients with bladder cancer. In addition, the authors attempted to test the hypothesis that plasma levels of MMPs are associated with time to cancer-related death. METHODS: Plasma MMP concentrations (MMP-1, -2, -3, -7, -8, -9, and -12) in 135 patients presenting with high-grade ≥T1 bladder cancer were measured. Data regarding clinical and pathologic features was ascertained in a retrospective fashion. RESULTS: The median duration of follow-up was 30.4 months. At the time of analysis, 61 patients had died, including 45 (33.3%) who died of bladder cancer. Plasma MMP-12 was not measurable. For all other MMPs, the intra-assay coefficient of variation varied from 6.12% to 9.82%. MMP-1, -2, -3, -8, and -9 were not found to be significantly associated with time to cancer-related death. Plasma MMP-7 levels were significantly associated with time to cancer-related death after adjustment for competing clinical and pathologic features (hazard ratio [HR], 2.2; 95% confidence interval [95% CI], 1.1-4.5 [P = .022]). The 5-year median cancer-specific survival rates for those patients with MMP-7 levels above and below the median value (300 pg/mL) were 73.6% (95% CI, 60.0-83.2%) and 48.0% (95% CI, 32.5-61.9%), respectively (P = .01). CONCLUSIONS: Multiplexed, particle-based flow cytometric assay allows for the high-throughput measurement of multiple plasma or serum proteins simultaneously. By using this new technology in a cohort of patients with bladder cancer, plasma levels of MMP-7 were identified as being significantly associated with time to cancer-related death.

AB - BACKGROUND: The current study was conducted to demonstrate the utility of a multiplexed, particle-based flow cytometric assay for the simultaneous analysis of a panel of matrix metalloproteinases (MMPs) using small volumes of plasma samples from patients with bladder cancer. In addition, the authors attempted to test the hypothesis that plasma levels of MMPs are associated with time to cancer-related death. METHODS: Plasma MMP concentrations (MMP-1, -2, -3, -7, -8, -9, and -12) in 135 patients presenting with high-grade ≥T1 bladder cancer were measured. Data regarding clinical and pathologic features was ascertained in a retrospective fashion. RESULTS: The median duration of follow-up was 30.4 months. At the time of analysis, 61 patients had died, including 45 (33.3%) who died of bladder cancer. Plasma MMP-12 was not measurable. For all other MMPs, the intra-assay coefficient of variation varied from 6.12% to 9.82%. MMP-1, -2, -3, -8, and -9 were not found to be significantly associated with time to cancer-related death. Plasma MMP-7 levels were significantly associated with time to cancer-related death after adjustment for competing clinical and pathologic features (hazard ratio [HR], 2.2; 95% confidence interval [95% CI], 1.1-4.5 [P = .022]). The 5-year median cancer-specific survival rates for those patients with MMP-7 levels above and below the median value (300 pg/mL) were 73.6% (95% CI, 60.0-83.2%) and 48.0% (95% CI, 32.5-61.9%), respectively (P = .01). CONCLUSIONS: Multiplexed, particle-based flow cytometric assay allows for the high-throughput measurement of multiple plasma or serum proteins simultaneously. By using this new technology in a cohort of patients with bladder cancer, plasma levels of MMP-7 were identified as being significantly associated with time to cancer-related death.

KW - Bladder cancer

KW - Matrix metalloproteinases

KW - MMP-7

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=77957163734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957163734&partnerID=8YFLogxK

U2 - 10.1002/cncr.25401

DO - 10.1002/cncr.25401

M3 - Article

C2 - 20572047

AN - SCOPUS:77957163734

VL - 116

SP - 4513

EP - 4519

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -